RT Journal Article
SR Electronic
T1 Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21260393
DO 10.1101/2021.07.13.21260393
A1 Prunas, Ottavia
A1 Warren, Joshua L.
A1 Crawford, Forrest W.
A1 Gazit, Sivan
A1 Patalon, Tal
A1 Weinberger, Daniel M.
A1 Pitzer, Virginia E.
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260393.abstract
AB The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel. We fit two time-to-event models – a mechanistic transmission model and a regression model – to estimate vaccine effectiveness against susceptibility to infection and infectiousness given infection in household settings. Vaccine effectiveness against susceptibility to infection was 80-88%. For breakthrough infections among vaccinated individuals, the vaccine effectiveness against infectiousness was 41-79%. The overall vaccine effectiveness against transmission was 88.5%. Vaccination provides substantial protection against susceptibility to infection and slightly lower protection against infectiousness given infection, thereby reducing transmission of SARS-CoV-2 to household contacts.One-Sentence Summary Vaccination reduced both the rate of infection with SARS-CoV-2 and transmission to household contacts in Israel.Competing Interest StatementDMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant from Pfizer on an unrelated topic. VEP is a member of the WHO Immunization and Vaccine-related Research Advisory Committee (IVIR-AC) and has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors declare that they have no competing interests. Funding StatementNational Institutes of Health grant R01AI137093 (JLW, DMW, VEP) National Institutes of Health grant 1DP2HD091799 (FWC) National Institutes of Health grant R01AI112970 (VEP) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Maccabi Healthcare Services' Institutional Review Board. Informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analyses. The analysis of the deidentified data was determined to be 'not human subject research' by the Yale IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the IMOH (Israeli Ministry of Health) regulations, individual-level data cannot be shared openly. Specific requests for remote access to deidentified data should be referred to the Maccabi Institute for Research & Innovation.